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Abstract
Background—Elevated levels of circulating liver enzymes have been associated with increased 
risk of cardiovascular disease. Their possible association with atrial fibrillation (AF) has received 
little attention.
Methods—We studied 9333 men and women, age 53–75, free of AF participating in the 
Atherosclerosis Risk in Communities Study followed up from 1996 to 2010. Aspartate 
aminotransferase (AST), alanine aminotransferase (ALT), and gamma glutamyl transpeptidase 
(GGT) were measured in stored plasma samples. Incident AF was ascertained from 
hospitalizations and death certificates. Associations between liver enzymes and AF incidence were 
assessed using multivariable Cox proportional hazards models.
Results—During a mean follow-up of 12 years, 1021 incident AF events were identified. Levels 
of AST, and to a lesser extent of ALT, showed a U-shaped association with AF risk, with higher 
AF risk among individuals in the two extremes of the distribution in minimally adjusted models. 
The associations were weakened after adjustment for potential confounders. In contrast, GGT, 
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modeled as log base 2, was linearly associated with AF risk after multivariable adjustment: a 
doubling of GGT levels was associated with a 20% increased risk of AF (95% confidence interval, 
10–30%). Additional adjustment for inflammatory markers did not appreciably affect the results. 
Associations were not different in men and women, in whites and blacks, among never drinkers of 
alcohol, and among those without prevalent heart failure.
Conclusions—In this community-based prospective study, higher levels of liver enzymes, 
mainly GGT, were associated with an increased risk of AF. The mechanisms underlying this 
association deserve further scrutiny.
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Introduction
Atrial fibrillation (AF) is the most commonly diagnosed cardiac arrhythmia in clinical 
practice. It affects >2 million people in the United States, and this figure is projected to 
double by 2050 [1]. Individuals with AF are at a substantially increased risk of stroke and 
overall mortality [2]. Therefore, considerable interest exists in identifying risk factors and 
biomarkers of AF risk. To date, numerous studies have shown that multiple variables 
contribute to an elevated risk for AF, including major cardiovascular risk factors and 
biomarkers involved in diverse pathways [3, 4, 5, 6].
Liver enzymes could be a potentially novel biomarker of AF risk. Circulating liver enzymes 
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are indicative of 
hepatocellular homeostasis and injury, and gamma glutamyl transpeptidase (GGT) reflects 
both liver injury and oxidative stress. Prior epidemiologic evidence suggests that circulating 
levels of liver enzymes, even in individuals without overt hepatic disease, might be 
associated with an increased risk of cardiovascular disease (CVD) [7], potentially due to 
their role as markers of nonalcoholic fatty liver disease (NAFLD) [8].
A recently published analysis from the Framingham Heart Study showed that higher levels 
of both ALT and AST were associated with an increased risk of AF, independently of 
alcohol consumption, among individuals free of clinical heart failure (HF) [9]. This 
association, however, needs to be replicated in large, independent prospective studies 
conducted in diverse populations. Also, no previous studies have assessed the association of 
GGT with AF incidence. Therefore, our objective was to assess the association of circulating 
liver enzymes (ALT, AST, GGT) with AF incidence in the Atherosclerosis Risk in 
Communities (ARIC) study, a large predominantly bi-racial community-based cohort.
Methods
Study population
The ARIC study is a prospective community-based study of CVD and its risk factors. At 
baseline (1987–89), 15,792 men and women age 45–64 were recruited from 4 communities 
in the US: Forsyth Co, NC; Jackson, MS; northwest suburbs of Minneapolis, MN; and 
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Washington County, MD. Additional exams were conducted in 1990–92 (Visit 2), 1993–95 
(Visit 3), 1996–98 (Visit 4), and 2011–2013 (Visit 5). Participants were mostly white in the 
Washington County and Minneapolis sites, exclusively black in Jackson, and mostly white 
and black in Forsyth County [10].
Liver enzymes were measured in plasma samples collected during Visit 4. Therefore, only 
individuals attending Visit 4 were included in this analysis (n=11,656). We excluded 
participants with unavailable data on liver enzymes or other covariates, race other than white 
or black, non-whites in the Minneapolis and Washington County field centers, prevalent AF 
at Visit 4, missing or unreadable electrocardiogram (ECG) at baseline, individuals with 
excessive alcohol intake (≥28 g/day in men and ≥14 g/day in women), and those with 
abnormal liver enzyme levels (ALT or AST ≥40 U/L or GGT ≥110 U/L), to avoid including 
individuals with liver disease. Numbers of excluded individuals are presented in Figure 1. 
After exclusions, 9,333 participants were eligible for the analysis. Institutional Review 
Boards at participating institutions approved the study protocol. All participants provided 
written informed consent.
Measurement of liver enzymes
ALT, AST, and GGT were measured in 2010–2011 from Visit 4 plasma samples (stored at 
−70°C since collection in 1996–1998) using an Olympus AU400e automated chemistry 
analyzer (Center Valley, PA) according to the manufacturer's protocol. Inter-assay 
coefficients of variation were 11.1% for ALT, 8.5% for AST and 9.3% for GGT.
Ascertainment of AF
In the ARIC study, AF diagnoses have been collected through 3 different approaches: ECGs 
done during the study exams, hospital discharge diagnoses, and death certificates [11, 12]. 
At each study exam, a standard supine 12-lead resting ECG was recorded with a MAC PC 
Personal Cardiograph (Marquette Electronics Inc, Milwaukee, WI) and transmitted to the 
ARIC ECG reading center for automatic coding. All AF cases automatically detected from 
the study ECG were visually checked by a cardiologist [13]. Information on hospitalizations 
during follow-up is obtained from annual follow-up calls and surveillance of local hospitals, 
with hospital discharge diagnoses codes collected by trained abstractors [14]. AF during 
follow-up was defined if International Classification of Disease (ICD) 9th edition Clinical 
Modification (ICD-9-CM) 427.31 or 427.32 diagnosis codes were present in any position; 
AF diagnoses recorded in the same hospitalization as open cardiac surgery were not 
included. Finally, AF was considered present if a death certificate included the ICD-9 code 
427.3 or ICD-10 code I48. We have previously shown that validity of AF ascertainment 
from hospital discharge codes is adequate.[11] For the present analysis, only cases 
ascertained from hospitalization discharge codes and death certificates after Visit 4 were 
included as incident cases, while study ECG-based cases and hospitalizations before Visit 4 
were used to define prevalent AF at Visit 4.
Assessment of other covariates
Information on other covariates was collected during Visit 4 from questionnaires and a 
physical examination, with the exception of education level, which was collected at Visit 1. 
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Smoking status, alcohol intake, and use of antihypertensive medication were self-reported. 
Weight and height were obtained with the participant wearing light clothing. Body mass 
index (BMI) was calculated as the weight in kilograms divided by height in meters squared. 
Blood pressure was measured with a random-zero sphygmomanometer after 5 minutes of 
rest in the sitting position and was defined as the average of 2 measurements taken. Diabetes 
was defined as fasting glucose ≥126 mg/dL, nonfasting glucose ≥200 mg/dL, treatment for 
diabetes, or a self-reported diagnosis of diabetes. Plasma N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP) was measured on a Cobas e411 analyzer using the Elecsys 
proBNP II immunoassay (Roche Diagnostics), and high-sensitivity C-reactive protein was 
measured with an immunonephelometric assay (Siemens Healthcare Diagnostics). Prevalent 
coronary heart disease (CHD) and HF at Visit 4 were defined as previously described [15].
Statistical analysis
We used Cox proportional hazards models to estimate the association of liver enzymes with 
incident AF with adjustment for potentially confounding variables. Time of follow-up was 
defined as the number of days between Visit 4 and AF ascertainment, death, lost to follow-
up, or December 31, 2010, whichever occurred earlier. In initial analyses, liver enzymes 
were modeled using restricted cubic splines to explore their dose-response shape. In separate 
models, liver enzymes were considered untransformed and after a logarithmic 
transformation; because log-transformed values provided better fit to the data, analyses were 
conducted with transformed liver enzymes. A base 2 log-transformation was used to 
facilitate interpretation of the coefficients: after this transformation, hazard ratios (HR) can 
be interpreted as the relative increase in the hazard of AF associated with a doubling of the 
level of the biomarker. The dose-response analysis suggested a linear association between 
GGT and AF, but non-linear associations for ALT and AST. Therefore, enzymes were 
categorized in quintiles, using the lowest risk quintile as the reference, which was the 3rd 
quintile for a U-shaped association with ALT and AST, and the 1st quintile for the linear 
association with GGT. Finally, because the AST/ALT ratio is considered a marker of liver 
injury due to alcohol, we conducted an additional analysis with this variable as the main 
exposure.
We compared several models. Model 1 included age, sex, race, and study center. Model 2 
included all variables in Model 1 plus BMI, diabetes mellitus, education level, ethanol 
intake, height, NT-proBNP, smoking, systolic blood pressure, use of antihypertensive 
medications, prevalent CHD, and prevalent HF as potential confounders of the association 
between liver enzymes and AF risk. Covariates for models 1 and 2 were selected based on a 
priori knowledge of risk factors for AF, as recommended elsewhere [16]. Finally, Model 3 
included all variables in Model 2 plus incident CHD and HF after Visit 4 modeled as time-
dependent covariates.
Several sensitivity analyses were conducted to evaluate the robustness of our results. First, 
we repeated the analysis excluding individuals with prevalent HF at Visit 4. Second, we 
conducted additional analyses adjusting for C-reactive protein, a biomarker of inflammation. 
Third, we assessed the association only among never drinkers. And, fourth, we conducted an 
analysis including individuals with elevated ALT or AST levels between 40 and 120 U/L, 
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and with elevated GGT levels between 110 U/L and 300 U/L. Finally, we tested the 
proportional hazards assumption including interaction terms between time and liver enzyme 
in the models, and exploring log(−log) survival curves. Interactions of age, sex, and race 
with liver enzyme levels were tested including multiplicative terms in the models.
Results
Among 9333 eligible participants free of AF at Visit 4, 1021 incident AF cases were 
identified during a mean of 12 years of follow-up. Table 1 and Supplementary Tables A1 
and A2 show characteristics of study participants according to baseline categories of the 
different liver enzymes. Overall, those with higher ALT and AST were more likely to be 
male, white, with higher alcohol intake, taller, and had lower levels of NT-proBNP, while 
those with higher GGT were more likely to be male, black, diabetic, with higher BMI and 
alcohol intake, higher systolic blood pressure and prevalent CVD, but lower NT-proBNP.
The association of log-transformed liver enzymes, modeled as restricted cubic splines, with 
the incidence of AF is presented in Figure 2. Both AST and ALT showed non-linear 
associations with AF incidence, while the association of GGT with AF was roughly linear. 
Table 2 provides HR and 95% confidence intervals (95%CI) of AF by quintiles of liver 
enzymes. Minimally adjusted models (Model 1) supported the presence of a U-shaped 
association of ALT and AST with AF incidence. After adjustment for potential covariates 
(Model 2), however, those with low ALT or AST levels did not have a higher risk compared 
to individuals with average levels, and a slightly elevated risk of AF was present only in 
those with high AST: in Model 2, the HR (95%CI) of AF among those in the highest 
quintile of ALT, compared to those in the middle quintile, was 1.11 (0.91–1.36), while the 
corresponding figure for AST was 1.28 (1.04–1.57) (Table 2, Model 2). Compared to those 
in the bottom quintile of GGT levels, those in the highest quintile had a 40% increased risk 
of AF (HR 1.44, 95%CI 1.17–1.77), with a clear linear dose-response association (p for 
trend = 0.0001). The HR (95%CI) for log2(GGT) as a continuous variable in the model was 
1.27 (1.17–1.38) after adjustment for age, sex, race and field center, and 1.20 (1.10–1.30) 
after additional adjustment for multiple confounders. No association was found between the 
AST/ALT ratio and AF risk (Supplementary Table A3)
In sensitivity analyses excluding 437 individuals with prevalent HF or after additionally 
adjusting for C-reactive protein, to reduce potential residual confounding, the results 
remained virtually unchanged (Supplementary Table A4), while restricting the analysis to 
the 2085 participants (221 AF events) that reported to be never drinkers, associations 
became slightly stronger, particularly for ALT and AST (supplementary table A5). We also 
conducted an additional analysis including 371 individuals (46 AF events) with elevated 
enzyme levels (between 40 and 120 U/L for ALT or AST, and between 110 and 300 U/L for 
GGT). The overall associations remained the same, with no strong evidence of a 
disproportionally elevated risk of AF among individuals in the highest group (supplementary 
table A6).
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No significant interactions between race, sex, or age and quintiles of liver enzyme levels 
were observed. Finally, we did not find evidence of violation of the proportional hazards 
assumption.
Discussion
In this community-based prospective cohort, we found moderately strong associations 
between circulating levels of liver enzymes and the incidence of AF. Levels of AST, and to 
a lesser extent of ALT, showed a U-shaped association with AF risk, while the association 
between GGT and AF risk was linear: a doubling of GGT levels was associated with a 20% 
increased risk of AF after adjustment for potential confounders. Exclusion of individuals 
with HF or adjustment for C-reactive protein, a marker of systemic inflammation, did not 
affect the results. The associations were similar in men and women, whites and blacks, and 
were observed even in individuals reporting no alcohol intake.
Different pathophysiological mechanisms can explain the association between liver enzymes 
and AF incidence. Excessive alcohol intake leads to elevated liver enzymes, particularly 
GGT [17], and could also increase risk of AF [18]. Nonetheless, no association was found 
between the AST/ALT ratio, a marker of liver injury due to alcohol use, and AF risk. 
Similarly, restricting the analysis to never drinkers did not alter the results, suggesting the 
existence of alternative mechanisms. Also, modest elevations of liver enzymes could be 
present in patients with hepatic congestion derived from right-sided HF [19]. However, the 
reported associations were evident even after adjustment for NT-proBNP and in individuals 
without HF. Liver enzymes are also elevated in the presence of NAFLD [20]. This hepatic 
condition is common and has been associated with an increased risk of CVD through several 
potential pathways [8]. For example, individuals with NAFLD are more likely to have 
insulin resistance, increased overall visceral adiposity, and be diagnosed with the metabolic 
syndrome [21]. Moreover, NAFLD is associated with low-grade inflammation and increased 
levels of oxidative stress [22, 23]. All these factors—metabolic syndrome, inflammation, 
oxidative stress—have been shown to be associated with an increased risk of AF, potentially 
explaining the observed associations [12, 24, 25]. Consistent with this hypothesized 
pathway, a recent cross-sectional study among type 2 diabetics found that presence of 
NAFLD, assessed by ultrasonography, was associated with the prevalence of AF, even after 
adjustment for confounders [26]. In our analysis, liver enzymes—as possible markers of 
NAFLD—were also associated with AF incidence even after adjustment for cardiometabolic 
risk factors and markers of inflammation. However, the weak, non-linear association of AF 
risk with ALT and AST, and the stronger association with GGT, a marker of systemic 
processes such as oxidative stress, argues that our observations may be more related to 
systemic rather than hepatic processes. Consistent with our results, some previous studies 
have found GGT to be more strongly associated with incident CVD than ALT or AST [7, 
27].
The published evidence on the association of circulating liver enzymes with AF is limited. 
An analysis including 3744 participants from the Framingham Study found that higher 
levels of ALT and AST were associated with an increased risk of AF in a linear fashion [9], 
but GGT was not evaluated. In contrast to our primary analysis, the Framingham Study 
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analysis included individuals with ALT or AST levels between 40 and 120 U/L. In our 
analysis, inclusion of individuals with levels between 40 and 120 did not change the overall 
shape of the association. Discrepancies between the Framingham Study analysis and our 
results could be due to differences in case ascertainment, the populations under study, or 
methods of covariate measurement. More recently, Targher and colleagues showed that 
GGT, but not ALT or AST, was associated with increased prevalence of AF among 
individuals with type 2 diabetes [26]. This association was attenuated after adjustment for 
ultrasonographically-defined NAFLD. To our knowledge, no other prospective studies have 
explored the association between circulating liver enzymes and AF risk.
Strengths and limitations
We should highlight some strengths of the present study. Our analysis included a large 
number of individuals from a diverse community-based cohort, with an adequate number of 
events to identify moderate associations. High-quality information on potential confounders 
was available and included in multivariable analyses. Also, losses to follow-up were kept to 
a minimum, reducing the risk of selection bias. Nonetheless, some limitations are evident. 
First, AF ascertainment relied mostly on hospitalization discharge codes, potentially missing 
asymptomatic cases and those managed exclusively in an outpatient setting. Previous 
studies, however, have showed adequate validity of this approach for epidemiologic studies 
[11, 28]. Second, circulating liver enzymes were only assessed once, which might lead to 
exposure misclassification due to within person-variability and the inability to investigate 
the impact of changes in these enzymes on AF risk. Third, we did not have information on 
the presence of valvular disease and, therefore, could not differentiate between valvular 
versus non-valvular AF. Finally, we focused on the study of associations, and not risk 
prediction. Given the only moderate strength of the observed associations (e.g. HR of 1.20 
per doubling of GGT), it is unlikely that circulating liver enzymes will make significant 
contributions to the predictive ability of existing risk prediction models for AF [29].
In conclusion, we found that circulating liver enzymes, particularly GGT, are associated 
with the incidence of AF independently of cardiometabolic factors and biomarkers of 
inflammation. The mechanisms underlying this association and the implications for primary 
prevention of AF, such as the potential impact of NAFLD treatment through lifestyle 
interventions or medications on AF risk, deserve further scrutiny.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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• What is already known about this subject?
∘ Numerous studies have identified possible biomarkers for the risk of 
atrial fibrillation (AF) risk. Elevated levels of circulating liver 
enzymes have been previously associated with cardiovascular 
disease, but their role as biomarkers of AF risk is not well defined.
• What does this study add?
∘ In a large, diverse community-based prospective study, we show 
that higher levels of gamma glutamyl transpeptidase, even at in the 
normal range, were associated with a higher risk of AF 
independently of other risk factors for, while the aspartate 
aminotransferase and alanine aminotransferase with AF risk was U-
shaped.
• How might this impact on clinical practice?
∘ Our results provide additional rationale to explore in more depth the 
role of liver dysfunction in the development of AF and the potential 
of gamma glutamyl transpeptidase as a biomarker of systemic 
processes related to AF.
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Flowchart of study participants, ARIC study, 1996–1998
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Association of blood liver enzymes with incidence of atrial fibrillation presented as hazard 
ratio (solid line) and 95% confidence intervals (shaded area). Results from enzyme-specific 
Cox proportional hazards model with log2(liver enzymes) modeled using restricted cubic 
splines, adjusted for age, sex, and race. Median value of the liver enzyme was considered the 
reference (HR=1). The histograms represent the frequency distribution of the liver enzymes 
in the study sample.
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≤13 U/L >13 U/L ≤18 U/L >18 U/L ≤21 U/L >21 U/L
N 5281 4052 5326 4007 4892 4441
Age, years 63.1 (5.7) 62.4 (5.6) 62.7 (5.7) 62.9 (5.6) 62.9 (5.7) 62.7 (5.6)
Female, % 67.1 45.5 63.3 50.4 67.1 47.4
Black, % 25.7 17.6 24.5 19.2 16.7 28.2
BMI, kg/m2 28.4 (5.8) 29.5 (5.3) 29.0 (5.8) 28.6 (5.3) 27.8 (5.4) 30.0 (5.7)
Current smoker, % 16.7 9.7 17.3 8.8 13.8 13.4
Diabetes, % 13.6 19.4 17.7 14.0 9.4 23.5
Ethanol intake, g/day 1.9 (4.5) 2.7 (5.5) 1.9 (4.5) 2.7 (5.4) 1.9 (4.2) 2.7 (5.6)
Height, cm 165.9 (8.9) 169.1 (9.5) 166.6 (9.1) 168.3 (9.4) 166.1 (9.0) 168.7 (9.4)
High school graduate, % 42.6 42.3 43.2 41.5 43.8 41.0
Systolic BP, mmHg 127.2 (19.6) 127.2 (18.2) 127.1 (19.3) 127.4 (18.6) 125.7 (19.1) 128.9 (18.7)
Antihypertensive medication, % 42.3 43.2 43.1 42.2 36.6 49.5
NT-proBNP, pg/mL* 75.9 (105.8) 49.4 (77.0) 65.8 (97.7) 59.5 (90.5) 74.7 (99.0) 52.2 (84.9)
Prevalent CHD, % 7.6 8.0 7.4 8.3 6.3 9.3
Prevalent HF, % 4.9 4.5 4.9 4.4 3.6 5.9
ALT, U/L 9.7 (2.4) 19.1 (5.1) 11.1 (3.9) 17.4 (6.4) 11.9 (4.7) 15.9 (6.6)
AST, U/L 16.3 (3.6) 21.3 (4.9) 15.2 (2.2) 22.8 (4.0) 17.5 (4.3) 19.6 (5.2)
GGT, U/L 21.3 (12.9) 30.2 (17.2) 22.6 (13.6) 28.6 (17.2) 15.1 (3.9) 36.3 (16.0)
Values correspond to means (standard deviation) or percentage, unless otherwise noted. ALT: alanine aminotransferase; AST: aspartate 
aminotransferase; BMI: body mass index; BP: blood pressure; CHD: coronary heart disease; GGT: gamma glutamyl transpeptidase; HF: heart 
failure
*
Geometric mean and interquartile range.
†
All baseline characteristics have p-values <0.05 for between-group comparison except for systolic BP, antihypertensive medications, prevalent 
CHD, and prevalent HF in ALT and AST and age in AST and GGT.
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Table 2
Hazard ratios (95% confidence intervals) of atrial fibrillation by quintiles of blood liver enzymes, ARIC 1996–
2010
ALT Q1 Q2 Q3 Q4 Q5 p-for trend*
Range, U/L 1–9 10–11 12–14 15–18 19–39
N 2299 1524 2051 1773 1686
AF Cases 261 159 216 191 194
Person-years 26,446 17,916 24,578 21,265 20,341
Model 1 1.21 (1.01–1.45) 1.05 (0.86–1.29) 1.00 (Reference) 1.02 (0.84–1.23) 1.12 (0.92–1.37) 0.29
Model 2 0.98 (0.82–1.18) 0.94 (0.77–1.16) 1.00 (Reference) 0.98 (0.81–1.19) 1.11 (0.91–1.36) 0.27
Model 3 0.96 (0.80–1.16) 0.94 (0.77–1.16) 1.00 (Reference) 0.92 (0.76–1.12) 1.05 (0.86–1.27) 0.60
AST Q1 Q2 Q3 Q4 Q5 p-for trend*
Range, U/L 5–15 16–17 18–19 20–22 23–39
N 2661 1786 1645 1612 1629
AF Cases 299 194 166 162 200
Person-years 31,033 21,146 19,934 19,220 19,213
Model 1 1.28 (1.06–1.55) 1.11 (0.90–1.36) 1.00 (Reference) 0.98 (0.79–1.22) 1.24 (1.01–1.52) 0.24
Model 2 1.06 (0.87–1.28) 1.09 (0.89–1.34) 1.00 (Reference) 1.01 (0.81–1.25) 1.28 (1.04–1.57) 0.19
Model 3 1.10 (0.90–1.33) 1.18 (0.96–1.45) 1.00 (Reference) 1.02 (0.82–1.27) 1.28 (1.04–1.58) 0.44
GGT Q1 Q2 Q3 Q4 Q5 p-for trend*
Range, U/L 2–14 15–18 19–24 25–33 34–109
N 2109 1649 2005 1743 1827
AF Cases 177 164 233 212 235
Person-years 25,731 19,617 23,823 20,314 21,060
Model 1 1.00 (Reference) 1.12 (0.90–1.38) 1.27 (1.04–1.56) 1.44 (1.17–1.76) 1.60 (1.31–1.95) <0.0001
Model 2 1.00 (Reference) 1.13 (0.91–1.40) 1.21 (0.99–1.48) 1.40 (1.14–1.73) 1.44 (1.17–1.77) 0.0001
Model 3 1.00 (Reference) 1.11 (0.90–1.38) 1.16 (0.95–1.42) 1.29 (1.04–1.59) 1.30 (1.06–1.60) 0.01
Model 1: Cox proportional hazards model adjusted for age, sex, race, and study site
Model 2: Cox proportional hazards model adjusted for Model 1 variables with additional adjustment for body mass index, diabetes mellitus, 
education level, ethanol intake, height, N-terminal proBNP, smoking, systolic blood pressure, use of antihypertensive medications, prevalent 
coronary artery disease, and prevalent heart failure
Model 3: Cox proportional hazards model adjusted for Model 2 variables with additional adjustment for incident coronary artery disease or heart 
failure as time-dependent covariates
*
P-value for linear trend in quintile number
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